Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma

• Verfasst von: Riedel, Frank [VerfasserIn]
• Verfasst von: Zaiss, Inka [VerfasserIn]
• Verfasst von: Herzog, Denise Julia [VerfasserIn]
• Verfasst von: Götte, Karl [VerfasserIn]
• Verfasst von: Naim, Ramin [VerfasserIn]
• Verfasst von: Hörmann, Karl [VerfasserIn]
• Titel: Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma
• Verf.angabe: Frank Riedel, Inka Zaiss, Denise Herzog, Karl Götte, Ramin Naim, Karl Hörmann (Department of Otolaryngology, Head and Neck Surgery, University Hospital of Heidelberg at Mannheim)
• E-Jahr: 2005
• Jahr: [July 2005]
• Umfang: 5 S.
• Fussnoten: Gesehen am 01.04.2022
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004
• Jahr Quelle: 2005
• Band/Heft Quelle: 25(2005), 4, Seite 2761-2765
• ISSN Quelle: 1791-7530
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: head and neck squamous cell carcinoma
• Sach-SW: Interleukin-6
• Sach-SW: serum level
• K10plus-PPN: 1797341790

Abstract

Interleukin (IL)-6 plays a central role as a differentiation and growth factor of tumor cells. IL-6 has been identified in a wide variety of malignancies, including head and neck squamous cell carcinomas (HNSCC). The aim of this study was to investigate the association between the serum levels of IL-6 in HNSCC patients and the biological characteristics of the tumor as well as the clinicopathological status of the patients. The circulating level of IL-6 in sera from patients with various HNSCC (n=90) as well as from healthy normal controls (n=39) was investigated. Serum IL-6 concentrations were determined as serum immunoreactivity using a quantitative sandwich enzyme immunoassay technique. For statistical analysis, the Kruskal-Wallis test was performed. The majority of the patients with HNSCC were found to have high serum IL-6 concentrations. The IL-6 levels in the sera of patients with cancer ranged from below the detection limit to 312.8 pg/ml (mean, 19.5 pg/ml). In contrast, the IL-6 serum levels in 39 healthy individuals ranged from below the detection limit to 52.2 pg/ml (mean, 6.0 pg/ml), with the concentration being significantly higher in HNSCC patients (p<0.001). Furthermore, the correlation of the IL-6 serum concentration with tumor stage was significant (p=0.04). Accordingly, there was a significant difference of IL-6 serum concentration of tumors with positive and negative lymph nodes (p=0.045), with concentration being significantly higher in lymph node-positive tumors. Our data on elevated IL-6 serum levels in the majority of HNSCC cancer patients and its correlation with tumor stage and lymph node status suggest that serum IL-6 reflects the proliferative activity of the tumor in patients with head and neck cancer. IL-6 serum determinations might serve as a biological marker and help to identify advanced head and neck tumors.